Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
Sanofi has said goodbye to Lexicon, but after years of failing to keep up with rivals, there is scope for the French drug maker to make more drastic cuts to its diabetes…
Having succeeded with cystic fibrosis Vertex is now chasing a cure for type 1 diabetes.
The Danish group tops the list, while Ardelyx could get its first nod for tenapanor, and Xeris gets a second shot with its hypoglycaemia rescue pen.
Setmelanotide looks approvable, but patients were stratified for inclusion in some measures.
Citing study failure, Sanofi terminates its tie-up with Lexicon covering Zynquista; not so fast, says Lexicon, and claims breach of contract.
Both Ardelyx and Rhythm Pharmaceuticals are looking for phase III clinical wins to kick off filing discussions for pipeline leads.
As placebo outperforms Cymabay’s seladelpar attention turns to the pivotal trial of Genfit’s elafibranor.
Lilly is still trying to find a therapeutic window following gastrointestinal issues with its brightest pipeline hope, the GIP/GLP1 agonist tirzepatide.